GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Additional Paid-In Capital

Noile-Immune Biotech (TSE:4893) Additional Paid-In Capital : 円4,025.1 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Additional Paid-In Capital?


Noile-Immune Biotech's quarterly additional paid-in capital stayed the same from Sep. 2023 (円4,023.8 Mil) to Dec. 2023 (円4,023.8 Mil) but then increased from Dec. 2023 (円4,023.8 Mil) to Mar. 2024 (円4,025.1 Mil).

Noile-Immune Biotech's annual additional paid-in capital increased from Dec. 2021 (円2,515.4 Mil) to Dec. 2022 (円2,765.4 Mil) and increased from Dec. 2022 (円2,765.4 Mil) to Dec. 2023 (円4,023.8 Mil).


Noile-Immune Biotech Additional Paid-In Capital Historical Data

The historical data trend for Noile-Immune Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Additional Paid-In Capital Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
1,324.37 2,515.36 2,765.40 4,023.82

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only - 3,998.67 4,023.82 4,023.82 4,025.10

Noile-Immune Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Noile-Immune Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines